No Data
Jiangsu Hengrui Pharmaceuticals (600276.SH): SHR-2173 injection has received the drug clinical trial approval notice.
On December 13, Glonghui reported that Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that its subsidiary, Guangdong Hengrui Pharmaceuticals Co., Ltd., has received the approval notice for clinical trials of SHR-2173 injection issued by the National Medical Products Administration and will begin clinical trials shortly. SHR-2173 injection is a self-developed Biological Product by the company that targets abnormally activated immune cells to exert anti-inflammatory and immune-suppressing biological effects, potentially reducing the levels of autoantibodies and improving the disease activity status of LN patients, providing new treatment options for patients.
Research Reports on the gold mine丨China Securities Co.,Ltd.: Jiangsu Hengrui Pharmaceuticals plans to initiate Listed in Hong Kong listing, accelerating international transformation, maintaining a "Buy" rating.
The Research Reports from CSC indicate that Jiangsu Hengrui Pharmaceuticals (600276.SH) plans to conduct an IPO in Hong Kong, which is expected to significantly promote the dual-driven strategy of technology innovation and internationalization, further supporting the development of the company's international business. At the same time, the company's innovative research and development continue to advance, with multiple data readouts for Innovative Drugs, and several progress made in overseas applications and authorizations. Future attention can be focused on: 18 NDA pipelines expected to be approved for market launch between Q4 2024 and 2025; data disclosure at academic conferences; potential overseas expansion and business development, etc.; and continuous volume growth of products after the implementation of medical insurance in 2025. Considering that the company's Innovative Drugs have good growth potential.
Jiangsu Hengrui Medicine's Subsidiaries Get Regulatory Nod to Trial Tumor Drug
Jiangsu Hengrui Pharmaceuticals (600276.SH): Injection SHR-4394 has received the drug clinical trial approval notice.
On December 10, Gelonghui reported that Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that the company and its subsidiary Shanghai Hengrui Pharmaceuticals Co., Ltd. received the approval notification for the clinical trial of the injectable SHR-4394 issued by the National Medical Products Administration, and the clinical trial will begin shortly. The injectable SHR-4394 is a therapeutic Biological Product independently developed by the company, intended for the treatment of prostate cancer.
Express News | Hengrui Pharmaceuticals Says It Plans to Seek Hong Kong Listing
Jiangsu Hengrui Pharmaceuticals (600276.SH): Planning to issue H shares stocks and related listing matters.
Gelonghui, December 9 - Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that in order to further promote the dual-driven global strategy of technology innovation and internationalization, and to assist in the development of the company's international business, the company plans to issue shares overseas (listed in Hong Kong) and list them on the main board of the Hong Kong Stock Exchange. The company will fully consider the interests of existing shareholders and the situation of the domestic and overseas capital markets, and complete the issuance and listing at an appropriate time and issuance window within the validity period of the shareholders' meeting resolution (i.e., 18 months from the date of approval by the company's shareholders' meeting or other agreed extended period).
Shareholders in Jiangsu Hengrui Medicine (SHSE:600276) Are in the Red If They Invested Three Years Ago
No Data
